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Abstract
Background: Traumatic brain injury (TBI) causes acute inflammatory responses that result in an enduring cascade
of secondary neuronal loss and behavioral impairments. It has been reported that progesterone (PROG) can inhibit
the increase of some inflammatory cytokines and inflammation-related factors induced by TBI. Toll-like receptors
(TLRs) play a critical role in the induction and regulation of immune/inflammatory responses. Therefore, in the
present study, we examined the genomic profiles of TLR-mediated pathways in traumatically injured brain and
PROG’s effects on these genes.
Methods: Bilateral cortical impact injury to the medial frontal cortex was induced in C57BL/6J mice. PROG was
injected (i.p., 16 mg/kg body weight) at 1 and 6 h after surgery. Twenty-four hours post-surgery, mice were killed
and peri-contusional brain tissue was harvested for genomic detection and protein measurement. RT-PCR arrays
were used to measure the mRNA of 84 genes in TLR-mediated pathways. Western blot, ELISA and
immunohistochemistry were used to confirm the protein expression of genes of interest.
Results: We found that 2 TLRs (TLR1 and 2), 5 adaptor/interacting proteins (CD14, MD-1, HSPA1a, PGRP and
Ticam2) and 13 target genes (Ccl2, Csf3, IL1a, IL1b, IL1r1, IL6, IL-10, TNFa, Tnfrsf1a, Cebpb, Clec4e, Ptgs2 and Cxcl10)
were significantly up-regulated after injury. Administration of PROG significantly down-regulated three of the 13
increased target genes after TBI (Ccl-2, IL-1b and Cxcl-10), but did not inhibit the expression of any of the detected
TLRs and adaptor/interacting proteins. Rather, PROG up-regulated the expression of one TLR (TLR9), 5 adaptor/
interacting proteins, 5 effectors and 10 downstream target genes. We confirmed that Ccl-2, Cxcl-10, TLR2 and TLR9
proteins were expressed in brain tissue, a finding consistent with our observations of mRNA expression.
Conclusion: The results demonstrate that TBI can increase gene expression in TLR-mediated pathways. PROG does
not down-regulate the increased TLRs or their adaptor proteins in traumatically injured brain. Reduction of the
observed inflammatory cytokines by PROG does not appear to be the result of inhibiting TLRs or their adaptors in
the acute stage of TBI.
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Background
Traumatic brain injury (TBI) comprises a cascade of
events that begins with a primary neuronal/glial insult
and progresses to further proximal and distal cell loss.
At the cellular level, the major effectors in this cascade
are the activation of inflammatory responses including
the release of cytokines, chemokines and adhesion mole-
cules, and the recruitment of leukocytes [1-6].
The neuroprotective action of progesterone (PROG) in
TBI has been extensively studied by our laboratory and
many others [7-11]. Given after a TBI, PROG has been
shown to attenuate cerebral edema, improve spatial
learning performance, reduce sensory neglect, and inhibit
the increase of some inflammatory cytokines and inflam-
mation-related factors, such as IL-1b, TNF-a, CFC3,
GFAP and NFкB [7-14]. How the various immunological
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and inflammatory responses in traumatically injured
brain are activated and regulated, and the mechanisms
underlying the neuroprotective effect of PROG against
TBI, have not been fully elucidated.
The important regulators that mediate much of the
inflammatory cascade are the Toll-like receptors (TLRs),
a trans-membrane receptor family that has emerged as a
key factor in the triggering of antimicrobial host defense
responses by the innate immune system (Figure 1). At
present, at least 10 human and 12 mouse TLRs have
been reported to be expressed in a variety of mamma-
lian immune-related cell types as well as non-immune
cells including microglia, astrocytes, oligodendrocytes
and neurons [15-21]. Each TLR recognizes its distinct
ligands derived from various microorganisms initiating
immunological and inflammatory responses [22,23]. For
instance, TLR2 recognizes peptidoglycans (PGN), TLR4
recognizes lipopolysaccharide (LPS), and TLR9 recog-
nizes viral CpG DNA [23]. Stressed and damaged cells
can also release endogenous ligands which activate
TLR-mediated signaling. Thus, immune inflammatory
responses can be activated by an injury without the pre-
sence of invading pathogens [24]. Upon activation by
exogenous and endogenous ligands, TLRs recruit a set
of adaptors, including MyD88, TIRAP, TRIF and
TRAM, and then activate downstream kinases and cellu-
lar signaling pathways which regulate the expression of
genes triggering inflammation and immunity [23,25,26].
Involvement of TLR-mediated signaling has been
reported in central nervous system (CNS) diseases such
as multiple sclerosis [27], Alzheimer’s disease, Parkin-
son’s disease, amyotrophic lateral sclerosis [28] and
ischemic brain damage [25,29-32]. Recently, increased
mRNAs for TLR1, 2, 4, 5, 7 and molecules associated
with TLR signaling was reported in spinal cord after
injury [33]. However, less is known about the genomic
profile of the TLR-mediated pathways in the traumati-
cally injured brain. Such knowledge could contribute to
Figure 1 Fold changes of TLRs after TBI and treatment with PROG. The figure shows the fold changes of Toll-like receptors (TLRs) after
traumatic brain injury (TBI) compared with the sham group. In the 10 detected TLRs, compared to sham controls, TLR1 and TLR2 genes were
significantly up-regulated (A, B). The TLR4 gene was up-regulated 1.9-fold (C). Progesterone (PROG) did not inhibit the increased TLRs, but
significantly up-regulated the expression of TLR9 in mice with and without TBI (D). Note: a: compared with Sham; b: compared with Sham+P;
d: compared with TBI; ≥2-fold, p < 0.05; Sham: n = 3; Sham+P: n = 3; TBI: n = 5; TBI+P: n = 3.
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a better understanding of the pathology of secondary
damage after brain injury and to the mechanisms of
action of PROG in enhancing neuroprotection after
injury. In the present study, RT2 Profiler PCR arrays
were used to detect the mRNA of 84 genes implicated
in regulating TLR pathways in mice with TBI. We then
examined the effect of PROG on the expression of these
genes. The protein expression of TLR2, TLR9, Ccl-2
and Cxcl-10 was also investigated.
Methods
Animals
Male C57BL/6J mice with body weights between 25 and
30 g were obtained from the Jackson Laboratory and
maintained in the Division of Laboratory Animal
Resources at Emory University. The experiments
outlined in this manuscript conform to the Guide for
the Care and Use of Laboratory Animals published by
the National Institutes of Health (NIH Publication No.
85-23, revised 1996). Animal care and experimental
protocols (150-2009) were approved by the Emory Uni-
versity Committee on Animal Care. Mice were assigned
to one of four groups: sham-injury control plus vehicle
(Sham, n = 11), TBI plus vehicle (TBI, n = 15), sham-
injury plus PROG treatment (Sham+P, n = 11), and TBI
plus PROG treatment (TBI+P, n = 13). PROG was pur-
chased from Sigma-Aldrich Co. (St. Louis, MO; Cat No.
7556). Based on the previous dose-response studies of
PROG in animals [14,34], we used a dose of 16 mg/kg
body weight. PROG was injected intraperitoneally (IP)
in Sham+P and TBI+P groups at 1 and 6 h after surgery.
The sham and TBI-only groups were injected with the
same volume of vehicle.
Induction of TBI
Bilateral cortical impact injury (CCI) to the medial fron-
tal cortex (MFC) has been previously described [35],
and was modified for mice in this experiment as follows:
mice were weighed and anesthesia was induced by 5.0%
isoflurane (Webster Veterinary Supply, Inc., Sterling,
MA). The scalp was shaved using electric hair clippers
and the exposed skin disinfected with iodine tincture.
The trachea was intubated with a 20-gauge intravenous
catheter. Anesthesia was maintained by inhalation of
1.5% to 2% isoflurane driven by oxygen flow by a
Laboratory Animal Anesthesia System (VetEquip,
Pleasanton, CA). The lungs were mechanically ventilated
at a rate of 110 breaths per min with a delivered tidal
volume of 0.5 ml. The mice were mounted in a stereo-
taxic device with their heads in a horizontal position.
Body core temperature was maintained at 37°C with a
homeothermic heating blanket system (TC-1000; CWE
Inc., Ardmore, PA). Blood SpO2 was monitored and
maintained at levels ≥90% using a SurgiVet™ pulse
oximeter (model V3304; Waukesha, WI). Under aseptic
conditions, the mice were secured in a prone position,
and a midline sagittal scalp incision was made using
sterile technique. A contusion was produced on the
exposed cortex (the anterior-posterior coordinate for the
epicenter of the injury was bregma - 1.0 mm) using a
magnetic impactor device. The impactor, containing a
2.0 mm diameter rod tip, compressed the cortex at
3.5 m/s to a depth of 1 mm with a dwell time of
100 ms. The incision was sutured and the mice were
allowed to achieve spontaneous respiratory effort prior
to extubation. Sham control animals underwent surgical
procedures identical to those for the TBI group, but no
impact was delivered. After awakening, the mice were
placed in a holding cage at 31°C for 2 hours and then
returned to their housing in the animal care room.
Preparation of tissue for extraction of RNA
Since most inflammatory factors increase within 24 h
after initial insult to brain and PROG is known to inhibit
many of these inflammatory factors in the early stage of
TBI, the time point of 24 h after injury was selected for
tissue analysis. Thus, 24 h after TBI and sham operations,
3 mice from the sham group, 5 mice from the TBI group,
3 mice from the Sham+P group and 3 mice from the TBI
+P group were killed and peri-contusional brain tissue
(brain area within 3 mm of the epicenter of the injury)
was harvested using a biopsy puncture (6 mm diameter),
snap-frozen in liquid nitrogen and stored at -80°C for
PCR array. To confirm the expressed genes are from
brain or blood-derived cells, 3 mice in each group were
euthanized, perfused with ice-cold PBS via the ascending
aorta, and then peri-contusional brain tissue (brain
area within 3 mm of the epicenter of the injury) was
harvested.
Extraction of RNA
RNA was extracted from the tissue using the TRIzol®
protocol (15596-026; Invitrogen, Carlsbad, CA). For
PCR array, after ethanol precipitation, the RNA was
further cleaned using SABiosciences’s RT2 qPCR-Grade
RNA Isolation Kit (PA-001; Frederick, MD) according
to the manufacturer’s protocol. RNA quality was
analyzed and met the required criteria for RT-PCR
arrays and RT-PCR TaqMan® Gene Expression Assays.
Real-time PCR arrays
RT-PCR arrays were performed by SABiosciences.
cDNAs were synthesized using an RT2 First Stand Kit
(SABiosciences) according to its protocol. The reaction
was performed at 42°C for 15 min and then stopped
immediately by heating at 95°C for 5 min. Mouse TLR
signaling pathway PCR array kits were purchased from
SABiosciences (PAMM-018). This kit profiles the
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expression of 84 genes related to TLR-mediated signal
transduction and 5 housekeeping genes (GUSB, HPRT1,
HSP90ab1, GADPH and ACTB). Genes are functionally
grouped as TLR, adaptor and interacting proteins, effec-
tors, downstream pathways and target genes, including
NFB pathway, JNK/p38 pathway, NF/IL6 pathway, IRF
pathway, and the regulation of adaptive immunity group
(Table 1). A negative control for genomic DNA and
contaminating RNA was also conducted in each sample.
Amplification, data acquisition, and the melting curve
were carried out by the ABI 7900 Real Time PCR
system (Applied Biosystems, Foster City, CA). The
PCR cycling program was set as follows: stage 1: 95°C
for 10 min, stage 2: 95°C for 15 sec followed by 60°C for
1 minute repeated for 40 cycles, and stage 3: 95°C for 15
sec, 60°C for 15 sec and 95°C for 15 sec. The cycle
threshold (Ct) and melting curve of each gene were
automatically established and recorded by the software.
Table 1 The detected genes of interest (GOI)
Fold Changes
Genes RefSeq TBI/Sham Sham+P/Sham TBI+P/TBI
Toll-like receptors
TLR1 NM_030682 2.99* 1.18 -1.33
TLR2 NM_011905 4.28* 2.82* 1.24
TLR3 NM_126166 1.20 1.82 1.20
TLR4 NM_021297 1.89* 1.54 1.05
TLR5 NM_016928 -1.28 1.49 1.47
TLR6 NM_011604 -1.12 1.88 1.70
TLR7 NM_133211 1.52 2.04 1.78
TLR8 NM_133212 1.79 3.44 1.55
TLR9 NM_031178 1.21 6.01* 3.31*
Muc13 NM_010739 1.15 -1.76 -1.39
Adaptors & interacting proteins
Btk NM_013482 1.56 1.81 1.24
Cd14 NM_009841 7.51* 1.00 -1.84
Hmgb1 NM_010439 -1.07 1.19 1.12
Hras1 NM_008284 -1.78 1.88 2.74*
Hspa1a NM_010479 1.97* 1.3 -1.37
Hspd1 NM_010477 1.05 -1.11 -1.21
MD-1 NM_010745 2.51* 1.06 1.02
Ly96 NM_016923 1.08 1.01 -1.07
Mapk8ip3 NM_013931 -1.09 -1.04 -1.06
MyD88 NM_010851 1.33 2.86* 2.65*
Peli1 NM_023324 -1.16 1.77 1.82
Pglyrp1 NM_009402 2.35* 1.64 1.34
Ripk2 NM_138952 1.10 1.18 1.04
Ticam1 NM_174989 -1.99 8.98* 16.18*
Ticam2 NM_173394 2.04* 4.87* 3.76*
Tirap NM_054096 1.24 2.93 2.04*
Tollip NM_023764 -1.09 1.12 1.11
Effectors
Casp8 NM_009812 -1.03 2.10* 2.04*
Fadd NM_010175 1.34 6.02* 4.63*
Irak1 NM_008363 -1.09 2.11 1.82
Irak2 NM_172161 -1.16 2.05* 2.58*
Map3k7 NM_172688 -1.31 -1.01 1.08
Nr2c2 NM_011630 -1.34 1.88 2.03*
Ppara NM_011144 -1.80 2.40* 2.72*
Eif2ak2 NM_011163 1.80 1.16 -1.37
Ube2n NM_080560 -1.15 1.02 -1.01
Ube2v1 NM_023230 -1.11 1.44 1.45
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Table 1 The detected genes of interest (GOI) (Continued)
Downstream and target genes
NFB pathway
Ccl2 NM_011333 41.89* 1.15 -2.73*
Chuk NM_007700 1.01 2.21 1.80
Csf2 NM_009969 1.50 1.67 -1.28
Csf3 NM_009971 3.07* 3.26* 2.32*
Hrb1 (agfg1) NM_010472 -1.18 1.58 1.52
IKKb NM_010546 -1.50 2.66* 3.10*
Il1a NM_010554 2.03* -1.23 -1.29
Il1b NM_008361 8.69* -1.17 -3.43*
Il1r1 NM_008362 2.16* 1.18 -1.28
Il2 NM_008366 -1.10 1.26 -1.45
Il6 NM_031168 5.17* -2.17* -2.33
Il10 NM_010548 2.06* 1.91 1.47
Il12a NM_008351 1.20 1.64 1.44
Map3k1 NM_011945 -1.28 2.70 1.78
Nfkb1 NM_008689 1.03 1.26 1.09
Nfkb2 NM_019408 1.14 3.86* 3.69*
Nfkbia NM_010907 1.22 1.29 1.35
Nfkbib NM_010908 1.15 -1.22 -1.18
Nfkbil1 NM_010909 -1.22 5.17* 4.83*
Nfrkb NM_172766 -1.20 1.65 1.47
Rel NM_009044 1.11 1.12 1.03
Rela NM_009045 -1.02 2.61* 2.6*
Tnf NM_013693 19.31* -1.05 -1.31
Tnfaip3 NM_009397 1.04 2.07* 2.38*
Tnfrsf1a NM_011609 2.91* 5.1* 3.31*
Tradd NM_001033161 1.09 -1.02 -1.14
JNK/p38 pathway
Elk1 NM_007922 -1.25 2.43* 2.13*
Fos NM_010234 1.67 1.99 1.34
Jun NM_010591 1.9* 1.56 1.1
Map2k3 NM_008928 1.40 1.28 -1.07
Map2k4 NM_009157 -1.26 -1.37 -1.34
Map3k1 NM_011945 -1.28 2.74 1.78
Mapk8 NM_016700 -1.45 1.73 1.94
Mapk9 NM_016961 -1.31 1.15 1.28
NF/IL6 pathway
Cebpb NM_009883 2.06* -1.19 -1.69
Clec4e NM_019948 6.72* -1.35 -1.43
Il6ra NM_010559 1.13 1.38 1.14
Ptgs2 NM_011198 2.33* 1.99* 1.5
IRF pathway
Cxcl10 NM_021274 22.99* -1.03 -4.46*
Ifnb1 NM_010510 1.03 -1.86 -1.66
Ifng NM_008337 1.30 1.01 1.19
Irf1 NM_008390 1.62 1.80 1.18
Irf3 NM_016849 0.99 3.12 1.90
Tbk1 NM_019786 -1.17 1.28 1.31
Adaptive Immunity
CD80 NM_009855 1.26 1.15 1.27
CD86 NM_019388 1.20 -1.11 1.00
Traf6 NM_009424 1.24 4.57* 3.19*
Note: Positive fold change indicates up-regulation. Negative fold change indicates down-regulation. *p < 0.05.
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The delta Ct (ΔCt) method was used for PCR array data
analysis. The normalized ΔCt) for each gene of interest
(GOI) was calculated by deducting the average Ct of the
5 housekeeping genes (HKG) from the Ct of each GOI.
Then the double delta Ct (ΔΔCt) for each GOI was
calculated by deducting the average ΔCt of GOI in the
sham group from the ΔCt of each GOI. The fold-change
of each GOI compared to the sham group was calcu-
lated as 2-ΔΔCt.
TaqMan® Gene Expression Assays
RT-PCR TaqMan® Gene Expression Assays were per-
formed using TaqMan real-time PCR primers and probes
for mouse TLR2 (Assay ID: Mm00442346_m1; RefSeq:
NM_011905.3), TLR9 (Assay ID: Mm00446193_m1;
RefSeq: NM_031178.2), Ccl-2 (Assay ID: Mm00441242_
m1; RefSeq: NM_011333.3), Cxcl-10 (Assay ID:
Mm00445235_m1; RefSeq: NM_021274.1), and Hprt1
(Assay ID: Mm00446968_m1; RefSeq: NM_013556.2)
purchased from Applied Biosystems. The synthesis of
cDNA was performed using iScript™ Reverse Transcrip-
tion Supermix for RT-qPCR (Bio-Rad, #170-8841)
according to its protocol at 42°C for 15 min and then
stopped immediately by heating at 95°C for 5 min. Real-
time PCR was performed on CFX96™ real-time PCR sys-
tem (Bio-Rad) in 96-well format and 25 μl reaction
volume per well using iQ Supermix (Bio-Rad, #170-
8862). Hprt1 control was used for normalization. Each
sample was measured in triplicate in a single RT-PCR
run. The cycling program was set as follows: stage 1: 95°
C for 10 min, stage 2: 95°C for 15 sec (for denaturation)
followed by 60°C (transcription) for 1 minute repeated
for 40 cycles, and stage 3: 95°C for 15 sec, 60°C for 15 sec
and 95°C for 15 sec. The double delta Ct (ΔΔCt) for each
GOI was calculated by deducting the average ΔCt of
GOI in the sham group from the ΔCt of each GOI. The
fold-change of each GOI compared to the sham group
was calculated as 2-ΔΔCt.
Western blot
Twenty-four hours after surgery, 16 mice (3 from the
sham group, 5 from the TBI group, 3 from the Sham+P
group and 5 from the TBI+P group) were euthanized,
perfused with ice-cold PBS via the ascending aorta until
the perfusion buffer was clear from the right atrium,
and then peri-contusional brain tissue (brain area within
3 mm of the epicenter of the injury) was harvested.
Western blot was performed as previously described
[31]. Briefly, proteins were extracted, electrophoresed
with SDS-polyacrylamide gel, and transferred onto
Hybond ECL membranes (Amersham Pharmacia, Piscat-
away, NJ). The ECL membranes were incubated with
primary antibody followed by incubation with peroxi-
dase-conjugated secondary antibodies. Signals were
detected with the ECL system (Amersham Pharmacia)
and quantified by scanning densitometry and computer-
assisted image analysis. The primary antibodies used
were anti-TLR2 (Santa Cruz Biotechnology, Inc.) and
anti-TLR9 (Abcam, Cambridge, MA). The specification
of the antibodies were confirmed in our previous study
and the data provided by the manufacture.
Enzyme-linked immunosorbent assay (ELISA)
Concentration of Ccl-2 and Cxcl-10 were examined by
ELISA using Ccl-2 and Cxcl-10 ELISA assay kits
(eBioscience Inc., San Diego, CA). For each sample, 10
μg of extracted protein was used for detection. The
procedure followed manufacturer instructions. The
absorbance was read on a spectrophotometer with a
wavelength of 450 nm and a reference wavelength of
650 nm. The concentrations of Ccl-2 and Cxcl-10 were
calculated according to the standard curve and
presented as pg/μg protein.
Immunohistochemistry (IHC) staining
Twenty-four hours after surgery, two mice from each
group were euthanized and perfused with ice-cold PBS
followed by 4% paraformaldehyde in PBS (PH = 7.4) via
the ascending aorta. Brains were removed, post-fixed in
4% paraformaldehyde for 24 h, and then stored at 4°C
in a solution of 30% sucrose-PBS for two days. The
brains were embedded in OCT and coronal sections
were cut 10 μm thick. TLR2 and TLR9 were co-stained
with specific markers for neurons (NeuN) and astrocytes
(GFAP). Immunofluorescent labeling was done by incu-
bating primary antibodies overnight at 4°C in humidified
chambers. The next day slides were rinsed 3 times with
TBS and incubated with directly conjugated secondary
antibodies for 1 h at room temperature. Slides were cov-
erslipped using aqueous mounting medium with DAPI.
The co-localization of TLR2 and TLR9 with specific
markers for neurons and astrocytes on the slide was
observed and analyzed under a confocal microscope
(Zeiss LSM 510). The first antibodies used were rabbit
anti-TLR2 (Abbiotec, San Diego, CA), rabbit anti-TLR9
(Abcam), rat anti-GFAP (Invitrogen) and mouse Fluor
488 conjugated anti-NeuN (Millipore, Billerica, MA).
The secondary antibodies used were Texas red conju-
gated donkey antibody to rabbit IgG (Abcam) and Cy2
conjugated goat antibody to rat IgG (Gene Tex, Inc,
Irvine, CA). The negative control slides went through
the same process except being incubated with primary
antibodies, which were replaced by antibody dilute
solution.
Statistical analysis
For PCR array and TaqMan® Gene Expression Assays,
the numbers of normalized ΔCt for each GOI were used
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for group comparison by one-way ANOVA with the All
Pairwise Multiple Comparison Procedures (Bonferroni t-
test). Genes that were up-regulated or down-regulated
by at least two-fold with p-value less than or equal to
0.05 were considered significant. The results from wes-
tern blotting and ELISA were presented as mean ± SE.
One-way ANOVA with All Pairwise Multiple Compari-
son Procedures (Bonferroni t-test) was used to compare
differences in groups.
Results
Changes in genes in TLR-mediated pathways after TBI
Of the 10 detected TLRs, TLR1 and TLR2 genes were
significantly up-regulated in the brain-injured group
compared to sham controls (≥2-fold, p < 0.05, Table 1,
Figure 1). The TLR4 gene was up-regulated 1.9-fold (p <
0.05). Five of the 17 detected adaptor and TLR-interacting
proteins (CD14, Hspa1a, Pglyrp-1, MD-1, and Ticam2)
were significantly up-regulated (≥2-fold, p < 0.05, Figure 2).
None of the detected effectors of TLR-signaling were up-
regulated more than 2-fold compared to the sham-oper-
ated group. Thirteen of 40 detected target genes of TLR
pathways (Ccl-2, Csf3, IL-10, IL-1a, IL-1b, IL1r1, IL-6,
TNF, Tnfrs1a, Cebpb, Clec4e, Ptgs2 and Cxcl-10) were
significantly up-regulated (≥2-fold, p < 0.05). Of the 84
detected genes, none was significantly down-regulated
more than 2-fold compared to shams (Figure 3).
Genes down-regulated by PROG in TBI
Administration of PROG significantly reduced the mRNA
expression of 3 of the increased genes in brain tissue after
TBI (Ccl-2, IL-1b and Cxcl-10; ≥2-fold, p < 0.05, Table 1
and Figure 3). PROG did not significantly down-regulate
the increased mRNA of TLRs, adaptor or TLR-interacting
proteins, or downstream target genes (Table 1, Figure 1
and 2).
Genes up-regulated by PROG in brain tissue
Administration of PROG significantly up-regulated
1 TLR (TLR9), 5 adaptor and interacting proteins (Hras1,
MyD88, Ticam1, Ticam2 and Tiap), 5 effectors (Casp8,
Fadd, Irak2, Nr2c2 and Paea), and 10 downstream target
genes (Csf3, Ikbkb, Lta, Nfkb2, Nfkbil1, Rela, Tnfaip3,
Tnfrsf1a, Elk1 and Traf6) in TLR pathways compared to
the untreated TBI group (Table 1).
Changes in selected genes and their encoded proteins
in TLR-mediated pathways in brain after
TBI and PROG treatment
The mRNA expression of selected genes, TLR2, TLR9,
Cxcl-10 and Ccl-2, was confirmed using TaqMan® Gene
Expression Assays in PBS-perfused brain tissue. The
results showed that these genes increased and/or
were modified by progesterone in brain tissue after TBI
(Figure 4), which are consistent with the results from the
Figure 2 Fold changes of adaptor and interacting proteins of TLR pathways after TBI and treatment with PROG. The figure shows the
fold changes of adaptor and interacting proteins after TBI compared with the sham group. CD14 (A), MD-1 (B), Pglyrp-1 (C) and Ticam2 (D)
were significantly up-regulated). PROG did not significantly inhibit the increased adaptor and interacting proteins, but significantly up-regulated
the expression of MyD88 (E) and Ticam1 (F) in mice with and without TBI compared with sham and TBI groups. Note: a: compared with sham;
b: compared with sham + p; d: compared with TBI; ≥2-fold and P < 0.05; Sham: n = 3; Sham+P: n = 3; TBI: n = 5; TBI+P: n = 3.
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PCR-array. To confirm the changes in the proteins
encoded by the genes in TLR-mediated pathways, we
detected protein levels of TLR2 and TLR9, and the con-
centrations of Ccl-2 and Cxcl-10 using western blotting
and ELISA in brain tissue from mice perfused with PBS.
Western blots demonstrated that TBI induced an increase
in TLR2, but not TLR9 24 h after injury (Figure 5A, B).
Treatment with PROG did not inhibit the increase of
TLR2. Rather, PROG increased the expression of TLR9
compared with untreated controls (Figure 5B). Results
from ELISA showed that the concentrations of Ccl-2 and
Cxcl-10 significantly increased in traumatically injured
brain, and that administration of PROG inhibited the
increase of Ccl-2 and Cxcl-10 24 hrs after TBI (Figure 5C,
D). To determine the cellular location of TLR2 and TLR9
in traumatically injured brain, IHC co-staining was
Figure 3 Fold changes of down-stream target genes in TLR pathways after TBI and treatment with PROG. The figures show the
up-regulated target genes of TLR pathways (Ccl-2, IL-1b, IL-1a, IL1r1, IL-6, TNF, Tnfrs1a, Clec4e, Cebpb, Jun, IRF-1 and Cxcl-10) after TBI compared
with shams. Administration of PROG significantly reduced the expression of 3 of the increased genes in brain tissue after TBI (Ccl-2 (A), IL-1b (B)
and Cxcl-10 (L) compared to TBI. Note: a: compared with sham; b: compared with sham + p; d: compared with TBI: ≥2-fold, p < 0.05; Sham:
n = 3; Sham+P: n = 3; TBI: n = 5; TBI+P: n = 3.
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performed using specific anti-bodies for TLR2, TLR9,
neuron mark (NeuN) and astrocyte marker (GFAP). TLR2
staining was evident in neurons in the cortex of injured
brain (Figure 6A, B, C). However, very little colocalization
of TLR2 with astrocytes was observed in the sections
(Figure 6D, E, F). Weak expression of TLR9 colocalized
with neurons was observed in cortex of the injured brain
(Figure 6G, H, I). Colocalization of TLR9 with astrocytes
was detected in the white matter of periventricular and
subcortical regions of the brain (Figure 6J, K, L).
Discussion
TLR-mediated signaling pathways in brain injury
A substantial literature now shows that TLR-mediated
signaling pathways play a critical role in the induction
and regulation of innate immune/inflammatory responses
which contribute to or amplify brain damage following
an injury [31,32]. It appears that most inflammatory
factors increase within 24 h after initial insult [1-6].
Given soon enough, PROG can inhibit many of these fac-
tors [10,36]. Because the injury cascade begins so quickly,
we chose to examine TLRs and related genes soon after
the initial trauma (24 h).
The present study demonstrated that two TLRs (TLR1
and TLR2) and five adaptor and interacting proteins
(CD14, HSPA1a, Pglyrp-1, MD-1, and Ticam2) were
significantly up-regulated by TBI (Table 1, Figure 1 and
2). Of the downstream target genes, 12 genes in the
MyD88-dependent pathway (Ccl-2, Csf3, Il10, Il1a, Il1b,
Il1r1, Il6, TNFa, Tnfrsf1a, Cebpb, Clec4e and Ptgs-2) and
only one in the TRIF-IRF pathway (Cxcl-0) increased in
brain tissue 24 h after TBI (Table 1 and Figure 3). The
results from western blotting and ELISA confirmed that
protein levels of TLR2, TLR9, Ccl-2 and Cxcl-10
increased in traumatically injured brain (Figure 5).
Immunohistochemistry co-staining demonstrated that
Figure 4 The mRNA levels of TLR2, TLR9, Ccl-2 and Cxcl-10 in traumatically injured brain with or without progesterone treatment.
The figures show that TLR2 (A), Ccl-2 (C) and Cxcl-10 (D) significantly increased in traumatically injured brain compared with sham controls.
Administration of PROG down-regulated the increased mRNA levels of Ccl-2 and Cxcl-10, but did not down-regulate the mRNA levels of TLR2
and TLR9 (B) in sham and injured brain. Note: a: compared with sham; d: compared with TBI: p < 0.05. Sham: n = 3; Sham+P: n = 3; TBI: n = 3;
TBI+P: n = 3.
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TLR2 was expressed mainly in neurons, and that TLR9
was expressed weakly in neurons, but stronger in astro-
cytes (Figure 6). A similar analysis in traumatically
injured spinal cord performed by Kigerl and colleagues
[33] showed that mRNA for TLR1, 2, 4, 5, 7, and mole-
cules associated with TLR signaling TLR, such as CD14,
MyD88, Traf6, Mal, Tollip, IкBa and NFкB, significantly
increased in injured spinal cord. Our results showing that
TLR1, TLR2 and CD14 increased after TBI are consistent
with Kigerl’s report. However, the expression of several
genes was different between spinal cord injury and TBI.
For example, increased TLR5 TLR7, MyD88, Traf6, IкBa
and NFкB were observed in spinal cord, but not in the
traumatically injured brain. This variation can be
explained by the different anatomic structures and
cellular distribution between brain and spinal cord. In
addition, the different injury models and time points
should also be considered.
Since TLR1 forms heterodimers with TLR2 and then
activates down-stream signaling through TLR2, we think
that TLR2-mediated signaling is an important pathway in
the pathology of TBI. In addition, HSPA1a functions as a
molecular chaperone and has been identified as an endo-
genous ligand of TLR2 or TLR4, which mobilizes NF-kB
and induces cytokine synthesis through its interaction
with TLR2 or TLR4 [37]. CD14 is an extracellular compo-
nent of TLR4 which functions as a co-receptor required
by the activation of TLR4 induced by lipopolysaccharide
(LPS) [23]. MD-1, also known as Ly86, interacting with
RP105, plays an important role in the TLR4 signaling
pathway [38,39]. Ticam2 physically bridges TLR4 and
TICAM-1 and functionally transmits LPS-TLR4 signaling
to TICAM-1, which in turn activates IRF-3 [40]. The
results show that the 5 adaptor and interacting proteins
up-regulated by TBI are closely related to TLR2 and
TLR4-mediated signaling. Moreover, the data showing
Figure 5 Expression of TLR2, TLR9, Ccl-2 and Cxcl-10 in traumatically injured brain with or without progesterone treatment. The
figures show that TLR2, Ccl-2 and Cxcl-10, but not TLR9, significantly increased in traumatically injured brain compared with sham controls.
Administration of PROG inhibited the increase of Ccl-2 and Cxcl-10, but increased the expression of TLR9 in sham and injured brain.
Representative images of western blots are shown on the top of A and B. Note: a: compared with sham; b: compared with TBI; d: compared
with TBI: p < 0.05. Sham: n = 3; Sham+P: n = 3; TBI: n = 5; TBI+P: n = 5.
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Figure 6 Immunohistochemical co-staining for TLR2 and TLR9 with NeuN and GFAP. IHC co-staining of TLR2 and TLR9 with specific
markers for neurons (NeuN) and astrocytes (GFAP) was performed and observed under a confocal microscope. The first antibodies used were
rabbit anti-TLR2, rabbit anti-TLR9, rat anti-GFAP and mouse Fluor 488 conjugated anti-NeuN. The secondary antibodies used were Texas red
conjugated donkey antibody to rabbit IgG and Cy2 conjugated goat antibody to rat IgG. The images show that TLR2 staining co-localized with
neurons in the cortex of injured brain (A, B, C). However, co-localization of TLR2 with astrocytes was hardly observed in the brain section (D, E,
F). Weak expression of TLR9 was observed co-localized with neurons in cortex of the injured brain (G, H, I). Co-localization of TLR9 with
astrocytes was detected in the white matter of periventricular and subcortical regions of the brain (J, K, L).
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that 12 down-stream target genes in the MyD88-depen-
dent pathway and only one in the TRIF-IRF pathway
(Cxcl10) increased in brain tissue, suggest that TBI most
likely activates the MyD88-dependent pathway rather than
the TRIF-dependent pathway.
We observed that the cytokines, Ccl-2, IL-1b, IL-6,
TNF and Cxcl-10 increased more than 5-fold in the TBI
group compared to sham controls. The inflammatory
cytokines encoded by these five genes are well-known
factors that can exacerbate secondary brain injury after
TBI. We take our data to indicate that TBI is one of
the stresses that up-regulates gene expression in
TLR-mediated signaling pathways and that TLR2/TLR4-
mediated MyD88-dependent pathways are the most
closely implicated in the unfolding pathophysiological
processes following TBI.
PROG affects TLR-mediated signaling pathways after
brain injury
Previous studies have indicated that PROG has multiple
functions in the CNS, regulating cognition, mood,
inflammation, mitochondrial function, neurogenesis and
regeneration, myelination, and recovery from TBI (for
recent reviews see [9,10,41]). Some PROG-regulated
neural responses are mediated directly by PROG recep-
tors (PR), which can be found in every neural cell type
in the brain [41]. The PRs regulate gene expression,
induce the transduction of signaling cascades, and
activate transcription factors [42,43].
Despite the large body of evidence suggesting that
PROG protects brain from traumatic injury and
improves functional outcomes, a full account of all the
mechanisms underlying PROG’s plieotropic and neuro-
protective effects is far from completed. In the present
study, administration of PROG significantly inhibited
the up-regulation of some of the genes coding inflam-
matory cytokines in traumatically injured brain tissue.
To our surprise, PROG did not down-regulate any of
the detected TLRs, adaptor proteins, effectors, and other
target genes in the TLR pathways. We take this finding
to mean that PROG can down-regulate some, but not
all, of the genes that encode inflammatory cytokine
expression after TBI. This effect may be mediated
through direct genomic regulation or through a variety
of other non-genomic mechanisms [41-44]. Clearly,
PROG did not affect the inflammatory response by inhi-
biting TLRs and their adaptor mRNA. PROG treatment
did significantly increase gene expression of one TLR
(TLR9), 5 adaptor/interacting proteins, 5 effectors and
10 downstream target genes (Table 1). Interestingly,
most of the genes that were increased by PROG were
not increased by TBI itself. The results from western
blot and ELISA also confirmed that PROG increased the
expression of TLR9 but not TLR2, and that PROG
inhibited the increase of Ccl-2 and Cxcl-10 induced by
TBI (Figure 5). Apparently PROG can regulate a num-
ber of TLR pathways by activating different functional
gene groups that could have more indirect effects on
the injury cascade and neural repair. It has been
reported that activation of TLRs, such as TLR9, induced
a neuroprotective effect on ischemic brain, which is
possibly mediated by suppressing proinflammatory
mediators and increasing neuroprotective factors [45].
Up-regulating genes in TLR-pathways may be one of a
number of different mechanistic pathways by which
PROG can protect the damaged brain from further
tissue loss and subsequent functional deterioration.
Given the fact that there are different pathways to neu-
roprotection, there is good reason to consider that com-
bination therapies that would address the different
signaling cascades initiated by CNS damage, would be a
better approach than hoping to find a single agent that
could ‘do it all’.
In future research we will need to identify the cellular
distribution and specific role of each functional gene
regulated by PROG following TBI. It is also important
to recognize that TBI and related disorders like stroke
have substantial systemic effects that, depending on
severity, are not limited to the brain [46,47]. There are
now over 180 publications from around the world using
more than 20 different injury models in 4 species,
including humans, demonstrating the neuroprotective
effects of PROG and its metabolites, so the effectiveness
of the neurosteroid is clear despite the fact that all of its
mechanisms of action are not yet known. Our findings
demonstrate that PROG protects brain from injury via
multiple mechanisms, such as including inhibition of
neurotoxicity factors, mediating TLR-pathways and
indirectly activating neuroprotective signaling.
Conclusion
Our study shows that TBI can increase gene expression
in TLR-mediated pathways, and profiles some of this
gene expression. Administration of PROG reduced the
up-regulation of genes encoding inflammatory cytokines
contributing to TBI, and mediated TLR signaling
pathways.
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